Bexion Pharmaceuticals
Bexion Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing innovative biologic therapies for treating solid tumors and chemotherapy-induced peripheral neuropathy (CIPN). Their lead candidate, BXQ-350, is a first-in-class biologic that modulates sphingolipid metabolism to target metastatic cancers and address neuropathic pain, with promising safety and efficacy data from clinical trials. The company aims to improve survival and quality of life for cancer patients through its novel therapeutics and is actively engaged in clinical research, including Phase 1b/2 trials and scientific presentations at major oncology conferences.
Industries
Nr. of Employees
small (1-50)
Bexion Pharmaceuticals
Covington, Kentucky, United States, North America
Products
Investigational sphingolipid-modulating biologic (protein-containing lipid nanovesicle)
An investigational biologic formulated as protein-containing phospholipid vesicles that modulates sphingolipid metabolism by activating enzymes to increase ceramides and lower sphingosine-1-phosphate; evaluated in preclinical models and early-phase clinical trials for solid tumors and CIPN.
Investigational sphingolipid-modulating biologic (protein-containing lipid nanovesicle)
An investigational biologic formulated as protein-containing phospholipid vesicles that modulates sphingolipid metabolism by activating enzymes to increase ceramides and lower sphingosine-1-phosphate; evaluated in preclinical models and early-phase clinical trials for solid tumors and CIPN.
Services
Clinical development and trial management
Design and conduct of early-phase oncology and pediatric clinical trials, including enrollment management and data collection for safety and efficacy endpoints.
Preclinical research and translational studies
In vitro and in vivo preclinical studies including neuronal cytoprotection assays, murine CIPN models, antiviral screening and translational biomarker analysis.
Formulation development and scale-up
Pre-formulation, formulation development and drug product scale-up for protein-based lipid vesicle biologics.
Biomarker and translational pharmacology services
Design and execution of biomarker-driven translational studies linking sphingolipid pathway modulation to clinical and preclinical endpoints.
Clinical development and trial management
Design and conduct of early-phase oncology and pediatric clinical trials, including enrollment management and data collection for safety and efficacy endpoints.
Preclinical research and translational studies
In vitro and in vivo preclinical studies including neuronal cytoprotection assays, murine CIPN models, antiviral screening and translational biomarker analysis.
Formulation development and scale-up
Pre-formulation, formulation development and drug product scale-up for protein-based lipid vesicle biologics.
Biomarker and translational pharmacology services
Design and execution of biomarker-driven translational studies linking sphingolipid pathway modulation to clinical and preclinical endpoints.
Expertise Areas
- Clinical trial management (Phase 1–2, pediatric)
- Oncology drug development (solid tumors)
- Chemotherapy-induced peripheral neuropathy (CIPN) research
- Translational pharmacology and biomarker development
Key Technologies
- Nanovesicle lipid formulation
- Saposin C-mediated sphingolipid activation
- Sphingolipid biomarker analysis (S1P, ceramide)
- High-content neuronal imaging assays